Sunstone Life Science Ventures

About The Fund

Sunstone Life Science Ventures is an independent European venture capital investment firm focused primarily on early-stage life science companies, laying the groundwork for novel therapeutics for humans. Founded in 2007 and headquartered in Copenhagen, Denmark, their mission is to seek out, enable, and empower the most promising life science therapeutics innovations, working to transform new science into products that improve patient outcomes and create value for innovators, investors, and healthcare systems globally. They manage their investments through a series of funds, with their latest, Fund IV, actively looking for new opportunities in the therapeutics space. The Sunstone team comprises individuals with extensive education, experience, and competencies relevant to the life science sector. Their portfolio includes a mix of currently active companies, completed mergers and acquisitions (M&A), and completed initial public offerings (IPOs). Sunstone Life Science Ventures has a rich history of contributing to the market entrance of several new drugs and supporting numerous clinical trials, including pre-clinical drug candidates, and clinical phase 1, 2, and 3 studies. They are supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI), aiming to facilitate financing and implementing productive investments within the EU and ensuring increased access to financing. Additionally, Sunstone Life Science Ventures emphasizes compliance with CSR and tax policies and demonstrates a commitment to sustainability, stating a clear policy on sustainability-related disclosures and the non-consideration of sustainability adverse impacts.